A series of N'-[3-(indole-1-sulfonyl) aryl]-N,N-dimethyl ethane-1,2-diamines and N'-[3-(indole-1-sulfonyl) aryl]-N,N-dimethyl propane-1,3-diamines was designed and synthesized as 5-HT6 receptor ligands. These compounds, when screened in a functional reporter gene-based assay, displayed potent antagonistic activity with Kb values in the range of 1.8-60 nM. The lead compound 9y has shown good ADME surrogate properties, acceptable pharmacokinetic profile and is active in animal models of cognition like novel object recognition test and Morris water maze. It was selected for detailed profiling.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/14756366.2014.889126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating the Mechanisms Involved in Scopolamine-induced Memory Degradation.
Arch Razi Inst
June 2024
Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
In the present study, the mechanisms involved in scopolamine-induced memory impairment have been investigated. The molecular events that take place during memory mostly include mechanisms that are seen in the acquisition phase. Results showed that one of the mechanisms of memory destruction caused by scopolamine, in addition to weakening the cholinergic system, is the indirect effect of scopolamine on other neurotransmitter systems, including the glutamatergic system.
View Article and Find Full Text PDFDesign of an innovative nanovehicle to enhance brain permeability of a novel 5-HT6 receptor antagonist.
Int J Pharm X
December 2024
Departamento de Farmacia, Facultad de Química, Pontificia Universidad Católica de Chile, Santiago, Chile.
An innovative nanovehicle based on lipid nanocapsules (LNC) was designed to facilitate the passage of a new 5-HT receptor antagonist, namely PUC-10, through the blood-brain barrier. PUC-10 is a new synthetic -arylsulfonylindole that has demonstrated potent 5-HT receptor antagonist activity, but it exhibits poor solubility in water, which indicates limited absorption. The lipid nanocapsules designed had a nanometric size (53 nm), a monomodal distribution (PI<0.
View Article and Find Full Text PDFLow-Basicity 5-HT Receptor Ligands from the Group of Cyclic Arylguanidine Derivatives and Their Antiproliferative Activity Evaluation.
Int J Mol Sci
September 2024
Department of Chemical Technology and Environmental Analytics, Faculty of Chemical Engineering and Technology, Cracow University of Technology, 24 Warszawska Street, 31-155 Cracow, Poland.
The serotonin 5-HT receptor (5-HTR), expressed almost exclusively in the brain, affects the Cdk5 signaling as well as the mTOR pathway. Due to the association of 5-HTR signaling with pathways involved in cancer progression, we decided to check the usefulness of 5-HTR ligands in the treatment of CNS tumors. For this purpose, a new group of low-base 5-HTR ligands was developed, belonging to arylsulfonamide derivatives of cyclic arylguanidines.
View Article and Find Full Text PDFPerspectives on obesity imaging: [F]2FNQ1P a specific 5-HT brain PET radiotracer.
Int J Obes (Lond)
January 2025
Lyon Neuroscience Research Center (CRNL), CNRS UMR5292, INSERM U1028, Université Lyon 1, Lyon, France.
Article Synopsis
- The study investigates how diet-induced obesity (DIO) affects serotonin subtype 6 receptors (5-HT) in the brains of Wistar rats, which are known to play a key role in appetite control and weight loss.
- Using MRI and PET scanning techniques, researchers monitored changes in 5-HT receptor density before and after a 10-week high-fat diet.
- Results showed that DIO led to increased body fat and higher binding of the 5-HT radiotracer in several brain regions, highlighting the potential of [F]2FNQ1P PET to study obesity-related changes in the brain.*
Predicting biological activity and design of 5-HT antagonists through assessment of ANN-QSAR models in the context of Alzheimer's disease.
J Mol Model
September 2024
São Carlos Institute of Chemistry, University of São Paulo, São Carlos, 13560-970, São Paulo, Brazil.
Context: Alzheimer's disease (AD) is the leading cause of dementia around the world, totaling about 55 million cases, with an estimated growth to 74.7 million cases in 2030, which makes its treatment widely desired. Several studies and strategies are being developed considering the main theories regarding its origin since it is not yet fully understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!